Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

NCT02437318 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

572

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Alpelisib
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals